ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2021

Jan 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2020-12-30

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-30	Common Stock	G	599	$0.00	Disposed	2544022	Direct
2021-01-01	Common Stock	A	800000	$0.00	Acquired	3344022	Direct

Footnotes

F1: Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of eight
predetermined performance goals related to the advancement of the Company's clinical and preclinical programs and business development that
must be achieved within four years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in
whole.

F2: Includes a total of 1,700,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals.
If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.